X @The Wall Street Journal

Financial Performance - Bristol Myers Squibb's bottom line increased by nearly $1 billion in Q3 [1] - Revenue climbed due to the strength of newer drugs [1] Cost Management - Costs came down, contributing to the increased bottom line [1]